23.07.2013 Views

il tumore della prostata. ii. stadiazione - Università degli studi di Pavia

il tumore della prostata. ii. stadiazione - Università degli studi di Pavia

il tumore della prostata. ii. stadiazione - Università degli studi di Pavia

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>Università</strong> <strong>degli</strong> Stu<strong>di</strong> <strong>di</strong> <strong>Pavia</strong><br />

AA 2010 - 2011<br />

Corso Integrato <strong>di</strong> Clinica Me<strong>di</strong>ca<br />

Insegnamento <strong>di</strong> Oncologia Me<strong>di</strong>ca<br />

IL TUMORE DELLA PROSTATA. II.<br />

STADIAZIONE<br />

Prof. Alberto Riccar<strong>di</strong>


STAGING METHODS


PROSTATIC CANCER<br />

Clinical staging. I.<br />

* TNM staging system includes categories for<br />

cancers palpable on DRE, those identified solely on<br />

basis of abnormal PSA (T1c), those palpable but<br />

clinically confined to gland (T2) and those extended<br />

outside gland (T3 and T4)


PROSTATIC CANCER<br />

Clinical staging. II.<br />

* DRE alone inaccurate in assessing extent of<br />

<strong>di</strong>sease within gland, capsular invasion, involvement<br />

of seminal vescicles and spread to nodal or more<br />

<strong>di</strong>stant sites;<br />

* assessment refined by imaging <strong>stu<strong>di</strong></strong>es<br />

[ultrasound, computed tomoghraphy (CT), magnetic<br />

resonance imaging (MRI) and bone scan];<br />

- however, no single test accurately pre<strong>di</strong>cts<br />

pathologic stage (organ - confined <strong>di</strong>sease? seminal<br />

vesical involvement? lymph node spread?)


PROSTATIC CANCER<br />

Clinical staging. III. Transrectal ultrasound<br />

* transrectal<br />

ultrasound (TRUS)<br />

most frequently used<br />

→ no consistent<br />

fin<strong>di</strong>ng pre<strong>di</strong>cts PC<br />

with certainty →<br />

primarly used to <strong>di</strong>rect<br />

prostate biopsy


* CT scans lack<br />

sensitivity and<br />

specificity for<br />

extraprostatic<br />

extension and<br />

inferior to MRI in<br />

visualization of<br />

lymph nodes<br />

PROSTATIC CANCER<br />

Clinical staging. IV. CT scan<br />

* CT scan can show abnormal lymph nodes in pelvis<br />

and abdomen, but not sensitive enough to identify<br />

microscopic cancer cells in lymph nodes = CT scans do<br />

not provide reliable enough information about con<strong>di</strong>tion<br />

of prostate or stage of prostate cancer


PROSTATIC CANCER<br />

Clinical staging. V. MRI<br />

* MRI (st<strong>il</strong>l lacking sensitivity and specificity) ↑ lymph<br />

node detection, especially of endorectal co<strong>il</strong>;<br />

[- T1 - weighted images: periprostatic fat and venous<br />

plexus, perivesicular tissues, lymph nodes, and bone<br />

marrow;<br />

- T2 - weighted images: internal architecture of prostate<br />

and seminal vesicles (low signal in most cancers, high<br />

signal in normal peripheral zone)];<br />

- MRI also useful for planning of surgery and ra<strong>di</strong>ation<br />

therapy<br />

= neither TC nor MRI accurately pre<strong>di</strong>cts pathologic<br />

stage at surgery


PROSTATIC CANCER<br />

Clinical staging. VII.<br />

Molecular <strong>di</strong>agnostic (experimental)<br />

* seeks to identify presence of<br />

circulating PC cells using an<br />

assay for PSA based on reverse<br />

transcriptase - polymerase<br />

chain reaction (RT - PCR) in<br />

leukocyte fraction of peripheral<br />

blood or bone marrow;<br />

- test+ in large % of pts with<br />

tumors seemingly confined to<br />

organ (unclear significance)


STAGING


STAGING<br />

* two schemes commonly used to stage PC;<br />

- TNM stage system: most common (by<br />

American Joint Committee on Cancer, AJCC),<br />

evaluating size of tumor, extent of involved<br />

lymph nodes, metastasis and cancer grade;<br />

- Whitmore - Jewett stage: now used less<br />

commonly for research, but often st<strong>il</strong>l used by<br />

clinicians


TNM STAGING


PROSTATIC CANCER<br />

TNM clinical staging<br />

* T categories:<br />

* clinically inapparent, not palpable tumor (T1a<br />

- T1b) or detected from ↑ serum PSA (T1c);<br />

* palpable but clinically confined to gland (T2),<br />

and:<br />

* extended outside gland (T3 and T4);<br />

* N categories: presence or absence of nodal<br />

metastases;<br />

* M categories: presence or absence of <strong>di</strong>stant<br />

metastases


PROSTATIC CANCER<br />

TNM clinical staging


PROSTATIC CANCER<br />

Clinical staging<br />

TNM definitions: T1<br />

* TX: primary tumor cannot be assessed;<br />

* T0: no evidence of primary tumor;<br />

* T1: clinically inapparent tumor not palpable nor<br />

visible by imaging:<br />

T1a: incidental histologic fin<strong>di</strong>ng in ≤ 5% of tissue<br />

resected;<br />

T1b: incidental histologic fin<strong>di</strong>ng in > 5% of tissue<br />

resected;<br />

T1c: identified by needle biopsy due to elevated PSA


* T2: confined within prostate:<br />

- T2a: involving 1 lobe;<br />

- T2b: involving both lobes;<br />

[- note: tumor found in 1 or both lobes by needle<br />

biopsy, but not palpable or visible by imaging,<br />

classified as T1c]<br />

PROSTATIC CANCER<br />

Clinical staging<br />

TNM definitions: T2


PROSTATIC CANCER<br />

Clinical staging<br />

TNM definitions: T3 - T4<br />

* T3: tumor extends through prostatic capsule:<br />

T3a: extracapsular extension (uni- or b<strong>il</strong>ateral);<br />

T3b: tumor invades seminal vesicle(s);<br />

[- note: invasion into prostatic apex or into (but not<br />

beyond) prostatic capsule is not classified as T3, but as<br />

T2];<br />

* T4: tumor fixed to or inva<strong>di</strong>ng adjacent<br />

structures other than seminal vesicles (bladder<br />

neck, external sphincter, rectum, levator muscles<br />

and / or pelvic wall)


LOCAL<br />

STAGING<br />

OF<br />

PROSTATE<br />

CANCER


PROSTATIC CANCER<br />

Clinical staging. TNM definitions: Regional nodes (N)<br />

* = nodes of true pelvis (= nodes below<br />

bifurcation of common <strong>il</strong>iac arteries, inclu<strong>di</strong>ng<br />

pelvic, hypogastric, obturator, <strong>il</strong>iac, periprostatic,<br />

and sacral);<br />

* <strong>di</strong>stant lymph nodes = outside confines of true<br />

pelvis (aortic, common <strong>il</strong>iac, inguinal, superficial<br />

inguinal, supraclavicular, cervical, scalene, and<br />

retroperitoneal nodes) and their involvement =<br />

<strong>di</strong>stant metastases;<br />

* NX: regional lymph nodes cannot be assessed;<br />

* N0: no regional lymph node metastasis;<br />

* N1: metastasis in regional lymph node(s)<br />

[- note: laterality does not affect N classification]


PROSTATIC CANCER<br />

Clinical staging. TNM definitions<br />

Distant metastasis (M)<br />

* MX: <strong>di</strong>stant metastasis cannot be assessed;<br />

* M0: no <strong>di</strong>stant metastasis;<br />

* M1: <strong>di</strong>stant metastasis;<br />

M1a: nonregional lymph node(s);<br />

M1b: bone(s);<br />

M1c: other site(s)


PROSTATIC CANCER<br />

Clinical staging: limits. I.<br />

* limit of TNM system = most PC are now<br />

<strong>di</strong>agnosed as T1c (by needle biopsy, often<br />

because ↑ PSA) or T2 (st<strong>il</strong>l confined within<br />

prostate) <strong>di</strong>sease, lea<strong>di</strong>ng to attempts at refining<br />

pre<strong>di</strong>ction of local <strong>di</strong>sease extent:<br />

- multiplex staging models (based on a<br />

combination of fin<strong>di</strong>ngs of <strong>di</strong>gital examination,<br />

biopsy, Gleason score and baseline PSA);<br />

- models based on no. of cores and % of each<br />

core involved by tumor;<br />

* unproven efficacy at pre<strong>di</strong>cting node<br />

involvement


PROSTATIC CANCER<br />

Variables in multiplex staging models


PROSTATIC CANCER<br />

Clinical staging. Differentiation (G)


Stage I<br />

T1a, N0, M0, G1<br />

Stage II<br />

T1a, N0, M0, G 2, 3 - 4<br />

T1b, N0, M0, any G<br />

T1c, N0, M0, any G<br />

T2, N0, M0, any G<br />

PROSTATIC CANCER<br />

AJCC stage groupings<br />

Stage III<br />

T3, N0, M0, any G<br />

Stage IV<br />

T4, N0, M0, any G<br />

any T, N1, M0, any G<br />

any T, any N, M1, any G


PROSTATIC CANCER<br />

AJCC stage groupings


STAGING<br />

WHITEMORE - JEWETT STAGING


PROSTATIC CANCER<br />

Whitemore - Jewett Staging System. Stage A<br />

* stage A = clinically undetectable tumor<br />

confined to prostate gland, as incidental<br />

fin<strong>di</strong>ng at prostatic surgery;<br />

- substage A1: G1 with focal involvement, usually<br />

left untreated;<br />

- substage A2: G2 - G3 or involving multiple foci<br />

in gland


Multicentricity of prostate cancer<br />

whole mount section of prostate showing two <strong>di</strong>stinct foci of<br />

adenocarcinoma <strong>il</strong>lustrating the frequent fin<strong>di</strong>ng of multicentricity


PROSTATIC CANCER<br />

Whitemore - Jewett Staging System. Stages B - C<br />

* stage B = confined to prostate gland:<br />

substage B0: nonpalpable, PSA - detected;<br />

substage B1: single nodule in 1 lobe;<br />

substage B2: more extensive involvement of 1 lobe or<br />

involvement of both lobes<br />

* stage C = clinically localized to periprostatic area<br />

but exten<strong>di</strong>ng through prostatic capsule, with<br />

seminal vesicles possibly involved:<br />

substage C1: clinical extracapsular extension;<br />

substage C2: extracapsular tumor producing bladder<br />

outlet or ureteral obstruction


PROSTATIC CANCER<br />

Whitemore - Jewett Staging System. Stage D<br />

* Stage D = metastatic <strong>di</strong>sease:<br />

substage D0: clinically localized <strong>di</strong>sease (prostate<br />

only) but persistently elevated enzymatic serum<br />

acid phosphatase titers;<br />

substage D1: regional lymph nodes only;<br />

substage D2: metastases to <strong>di</strong>stant lymph nodes,<br />

bone or visceral organs;<br />

substage D3: D2 prostate cancer pts who<br />

relapsed after adequate endocrine therapy


STAGING<br />

COMPARISON BETWEEN TNM AND<br />

WHITEMORE - JEWETT STAGING


CLINICAL STAGES<br />

BY TNM CLASSIFICATION<br />

AND<br />

WHITMORE - JEWETT<br />

STAGING SYSTEM

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!